HuMOLYTE®: A Breakthrough in Mitigating Chemotherapy-Induced GI Side Effects
Dr. Sourabh Kharait presented a compelling study at the recent Microbiome & Probiotic R&D & Business Collaboration Forum, focusing on Humolyte®, an innovative oral rehydration solution designed to alleviate gastrointestinal (GI) side effects associated with chemotherapy. Chemotherapy drugs, while essential in treating cancer, can severely damage the GI tract, leading to side effects such as mucositis, inflammation, and dehydration. These symptoms often require additional medical intervention, such as intravenous rehydration.
Humolyte® combines a magnesium-rich electrolyte solution with the human milk oligosaccharide (HMO) 2’-fucosyllactose (2’-FL), which has known benefits for supporting gut health. This study evaluated Humolyte®’s effectiveness in a Wistar rat model, aiming to protect and strengthen the GI barrier, thereby reducing chemotherapy-related GI toxicity.
Study Highlights
Reduced GI Injury: Wistar rats that received Humolyte® before chemotherapy exhibited less severe intestinal and oral tissue damage, as evidenced by lower histopathology scores for inflammation and epithelial damage.
Weight Loss Mitigation: Pre-treatment with Humolyte® significantly reduced weight loss in rats, suggesting it can counteract chemotherapy-induced wasting.
Improved Cell Health: In vitro studies showed that Humolyte® enhanced the viability of goblet cells (cells responsible for mucin production in the GI tract), boosting mucin secretion and maintaining epithelial integrity.
Promising Diarrhea Control: Compared to control groups, Humolyte® notably reduced diarrhea severity, indicating its potential for managing this common chemotherapy side effect.
Future Directions
Building on the promising results of the rat model, Dr. Kharait’s team plans to conduct clinical trials in humans. These trials will evaluate the effects of Humolyte® on GI health, mucositis severity, and the gut microbiome in patients undergoing chemotherapy.
This research suggests that Humolyte® could fill a crucial gap in supportive cancer care, offering a safe, non-invasive means to alleviate chemotherapy's "off-target" GI effects.
To learn how HuMOLYTE can aid in hydrating patients during chemotherapy and alleviating chemotherapy side effects, visit here.
About Dr. Sourabh Kharait
Dr. Sourabh Kharait (MD / PhD) is Clinical Nephrologist and Medical Director of Clinical Trials at Summit Nephrology Medical Group, and the Founder and CEO of IGH Naturals, a platform company that designs Functional Foods and Nutritional products for athletes and patients with chronic diseases.
